

**Rh(III)-catalysed synthesis of cinnolinium and
fluoranthemium salts by using C-H activation/annulation
reactions: Organelle specific mitochondrial staining
application**

Sivakalai Mayakrishnan,^a Masilamani Tamizmani,^b Chandrasekar Balachandran,
^c Shin Aoki, ^c Narayanan Uma Maheswari^{a*}

^a Organic & Bioorganic Chemistry Laboratory, CSIR-Central Leather Research Institute, Adyar, Chennai-600 020, India.

Corresponding author; 044-24437120, E-mail: umamaheswari@clri.res.in

^b State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai, 200032, China


^c Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan

**Electronic
Supporting Information**

Table of Contents


1. Parallel competitive reaction	3
2. H to D exchange experiments	5
3. Photoluminescence spectrum.....	7
4. Copy of ^1H , ^{13}C and HRMS spectra.....	16
5. DFT Calculations	56
6. Reference	67

1. Parallel competitive reaction



Scheme S1


A solution of 2-phenyl-2H-indazole **1a** (58 mg, 0.3 mmol), 1,2-di-p-tolylethyne **2b** (62 mg, 0.3 mmol), AgBF_4 (58 mg 0.3 mmol), $[\text{RhCp}^*\text{Cl}_2]_2$ (9.0 mg, 5.0 mol %), and $\text{Cu}(\text{OAc})_2$ (54 mg 0.3 mmol) in 1,2-DCE (3 mL). The tube was sealed with a Teflon-coated screw cap and the reaction solution was heated at 110 °C for 3 hours. At the same time, another solution of 2-phenyl-2H-indazole **1a** (58 mg, 0.3 mmol), 1,2-bis(4-chlorophenyl)ethyne **2d** (74 mg, 0.3 mmol), AgBF_4 (58 mg 0.3 mmol), $[\text{RhCp}^*\text{Cl}_2]_2$ (9.0 mg, 5.0 mol %), and $\text{Cu}(\text{OAc})_2$ (54 0.3 mmol) in 1,2-DCE (3 mL). The tube was sealed with a Teflon-coated screw cap and the reaction solution was heated at 110 °C for 3 hours. After cooling ambient temperature, the solvent was removed from both the reaction mixtures under reduced pressure and the residues of the reaction mixtures were separately purified by silica gel (100-200 mesh) column chromatography using Methanol/DCM as the eluant to afford **3e** 32% and **3g** 24% (**3e**:**3g** = ~1.3:1).



Scheme S2

A solution of 5,6-diphenylindazolo[2,3-a]quinoline **1a** (111 mg, 0.3 mmol), 1,2-di-p-tolylethyne **2c** (61 mg, 0.3 mmol), AgBF₄ 58 mg (0.3 mmol), [RhCp*Cl₂]₂ (9 mg, 5.0 mol %), and Cu(OAc)₂ (0.3 mmol) in 1,2-DCE 3.0 mL. The tube was sealed with a Teflon-coated screw cap and the reaction solution was heated at 110 °C for 3 hours. At the same time, another solution of 2-phenyl-2H-indazole **1a** (111 mg, 0.3 mmol), 1,2-bis(4-chlorophenyl)ethyne **2d** (74 mg, 0.3 mmol), AgBF₄ 58 mg (0.3 mmol), [RhCp*Cl₂]₂ (9 mg, 5.0 mol %), and Cu(OAc)₂ (0.3 mmol) in 1,2-DCE 3 ml. The tube was sealed with a Teflon-coated screw cap and the reaction solution was heated at 110 °C for 3 hours. After cooling ambient temperature, the solvent was removed from both the reaction mixtures under reduced pressure and the residues of the reaction mixtures were separately purified by silica gel (100-200 mesh) column chromatography using Methanol/DCM as the eluant to afford **5b** 30% and **5d** 47% (**5b**:**5d** = ~1.7:1.0)

2. H to D exchange experiments



Scheme S3

To an oven-dried 20 mL reaction tube with septum containing were added 2-phenyl-2H-indazole **1a** 58.2 mg (0.3 mmol, 1.0 equiv), $[\text{RhCp}^*\text{Cl}_2]_2$ (9.18 mg, 0.015 mmol, 0.05 equiv), $\text{Cu}(\text{OAc})_2$ 55.6 mg, (0.3 mmol, 1.0 equiv), Acetic acid-*d*₄ 0.38 ml (20.0 equiv) and 1,2-DCE 3.0 ml. The reaction mixture was heated at 110 °C for 12 h. After the reaction mixture was cooled to room temperature diluted with CH_2Cl_2 , filtered through celite and the filtrate was concentrated under reduced pressure. After that, purification was performed by column chromatography on silica gel using hexane and ethyl acetate (90:10) as eluent. Desired product colourless solid **1a-d₃** 52 mg was obtained in 90% of yield. The H/D exchange was found to be 76% at the protons attached to C-2 and C-5 in the recovered 2-phenyl-2H-indazole **1a-d₃**. Also found H/D exchange 25% at the indazole 2-*H* position. These results also clearly reveal that the C-H bond activation as a key intermediate in the reaction as well as it is the reversible process.





Figure S11: Preliminary mechanistic study



Scheme S4

To an oven-dried 20 mL reaction tube with septum containing were added 2-phenyl-2H-indazole **1a** 58 mg (0.3 mmol, 1.0 equiv), diphenylacetylene **2a** 52 mg (0.3 mmol), AgBF_4 58 mg (0.3 mmol%), $[\text{RhCp}^*\text{Cl}_2]_2$ (9 mg, 0.015 mmol, 0.05 equiv), Cu(OAc)_2 56 mg, (0.3 mmol, 1.0 equiv), acetic acid- d_4 0.38 ml (20.0 equiv) and 1,2-DCE 3.0 ml. The reaction mixture was heated at 110 °C for 12 h. After the reaction mixture was cooled to room temperature diluted with CH_2Cl_2 , filtered through celite and the filtrate was concentrated under reduced pressure. After that, purification was performed by column chromatography on silica gel using DCM and Methanol (95:5) as eluent. Desired product colourless solid **3a** was obtained in 78% of yield.

3. Photoluminescence spectrum




Figure SI2: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **3a**




Figure SI3: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **3b**




Figure SI4: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **3c**




Figure SI5: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **3d**




Figure SI6: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **3f**




Figure SI7: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **4g**




Figure SI8: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **3h**




Figure SI9: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5a**




Figure SI10: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5b**




Figure SI11: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5c**




Figure SI12: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5d**




Figure SI13: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5e**




Figure SI14: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5f**




Figure SI15: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5g**




Figure SI16: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5h**




Figure SI17: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5i**




Figure S118: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5j**




Figure S119: Normalized absorption (black), Fluorescence in DCM (red) spectra of compound **5k**

4. Copy of ^1H , ^{13}C and HRMS spectra




Figure S20: ^1H NMR spectrum of compound **3a** in CDCl_3




Figure S21: ^{13}C NMR spectrum of compound **3a** in CDCl_3




Figure S22:DEPT-135 NMR spectrum of compound **3a** in CDCl₃




Figure S23: ¹⁹F spectrum of compound **3a**




Figure S24: ^{11}B spectrum of compound **3a**




Figure S25: ^1H NMR spectrum of compound **3b** in CDCl_3




Figure S26: ^{13}C NMR spectrum of compound **3b** in CDCl_3




Figure S27: DEPT-135 NMR spectrum of compound **3b** in CDCl_3




Figure S28: HRMS spectrum of compound **3b**




Figure S29: ¹H NMR spectrum of compound **3c** in CDCl₃




Figure S30: ^{13}C NMR spectrum of compound **3c** in CDCl_3




Figure S31: DEPT-135 NMR spectrum of compound **3c** in CDCl_3




Figure S32: HRMS spectrum of compound **3c**




Figure S33: ^1H NMR spectrum of compound **3d** in CDCl_3




Figure S34: ^{13}C NMR spectrum of compound **3d** in CDCl_3




Figure S35: HRMS spectrum of compound **3d**




Figure S36: ^1H NMR spectrum of compound **3e** in CDCl_3




Figure S37: ^{13}C NMR spectrum of compound **3e** in CDCl_3




Figure S38: DEPT-135 NMR spectrum of compound **3e** in CDCl_3




Figure S39: HRMS spectrum of compound **3e**




Figure S40: ^1H NMR spectrum of compound **3f** in CDCl_3




Figure S41: ^{13}C NMR spectrum of compound **3f** in CDCl_3




Figure S42: DEPT-135 NMR spectrum of compound **3f** in CDCl_3






Figure S43: HRMS spectrum of compound **3f**






Figure S46: DEPT-135 NMR spectrum of compound **3g** in DMSO- d_6




Figure S47: HRMS spectrum of compound **3g**




Figure S48: ¹H NMR spectrum of compound **3h** in DMSO-d₆




Figure S49: ¹³C NMR spectrum of compound **3h** in DMSO-d₆




Figure S50: DEPT-135 NMR spectrum of compound **3h** in DMSO-*d*₆




Figure S51: HRMS spectrum of compound **3h**




Figure S52: ^1H NMR spectrum of compound **5a** in CDCl_3




Figure S53: ^{13}C NMR spectrum of compound **5a** in CDCl_3




Figure S54: DEPT-135 NMR spectrum of compound **5a** in CDCl_3




Figure S55: HRMS spectrum of compound **5a**




Figure S56: ¹⁹F spectrum of compound 5a




Figure S57: ¹¹B spectrum of compound 5a




Figure S58: ^1H NMR spectrum of compound **5b** in CDCl_3




Figure S59: ^{13}C NMR spectrum of compound **5b** in CDCl_3




Figure S60: DEPT-135 NMR spectrum of compound **5b** in CDCl_3




Figure S61: HRMS spectrum of compound **5b**




Figure S62: ¹H NMR spectrum of compound **5c** in CDCl₃




Figure S63: ¹³C NMR spectrum of compound **5c** in CDCl₃




Figure S64: DEPT-135 NMR spectrum of compound **5c** in CDCl_3




Figure S65: HRMS spectrum of compound **5c**




Figure S66: ^1H NMR spectrum of compound **5d** in CDCl_3




Figure S67: ^{13}C NMR spectrum of compound **5d** in CDCl_3




Figure S68: DEPT-135 NMR spectrum of compound **5d** in CDCl_3




Figure S69: HRMS spectrum of compound **5d**




Figure S70: ^1H NMR spectrum of compound **5e** in CDCl_3




Figure S71: ^{13}C NMR spectrum of compound **5e** in CDCl_3




Figure S72: DEPT-135 NMR spectrum of compound **5e** in CDCl_3




Figure S73: HRMS spectrum of compound **5e**




Figure S74: ^1H NMR spectrum of compound **5f** in CDCl_3




Figure S74: ^{13}C NMR spectrum of compound **5f** in CDCl_3

131.56
131.45
131.31
130.79
130.69
130.37
130.27
130.22
130.12
129.78
129.70
129.67
129.59
129.55
129.52
129.26
129.22
129.14
129.12
129.07
129.05
128.99
128.87
128.80
128.73
128.66
128.59
128.10
127.98
127.30
127.25
125.35
124.06
122.76
113.31

21.42
21.40





Figure S75: DEPT-135 NMR spectrum of compound **5f** in CDCl₃




Figure S76: HRMS spectrum of compound **5f**




Figure S79: DEPT-135 NMR spectrum of compound **5g** in CDCl_3




Figure S80: HRMS spectrum of compound **5g**




Figure S81: ^1H NMR spectrum of compound **5h** in CDCl_3




Figure S82: ^{13}C NMR spectrum of compound **5h** in CDCl_3




Figure S83: DEPT-135 NMR spectrum of compound **5h** in CDCl_3




Figure S84: HRMS spectrum of compound **5h**




Figure S85: ^1H NMR spectrum of compound **5i** in CDCl_3




Figure S86: ^{13}C NMR spectrum of compound **5i** in CDCl_3




Figure S87: DEPT-135 NMR spectrum of compound **5i** in CDCl₃




Figure S88: HRMS spectrum of compound **5i**




Figure S89: ^1H NMR spectrum of compound **5j** in CDCl_3




Figure S90: ^{13}C NMR spectrum of compound **5j** in CDCl_3




Figure S91: DEPT-135 NMR spectrum of compound **5j** in CDCl_3




Figure S92: HRMS spectrum of compound **5j**




Figure S93: ^1H NMR spectrum of compound **5k** in CDCl_3




Figure S94: ^{13}C NMR spectrum of compound **5k** in CDCl_3




Figure S95: HRMS spectrum of compound 5k+5k'




Figure S96: ¹H NMR spectrum of compound 5l in CDCl₃




Figure S97: ^{13}C NMR spectrum of compound **5I** in CDCl_3




Figure S98: HRMS spectrum of compound **5I+5I'**

5. DFT Calculations

Table 2. Data of DFT studies¹

Method Compound	B3LYP/6-311G*		
	LUMO (eV)	HOMO (eV)	Gap (eV)
3a	-5.6346	-9.2603	3.6257
3b	-5.6934	-9.1038	3.4104
3c	-5.6850	-9.0847	3.3997
3d	-5.7168	-9.3781	3.6613
3e	-5.7206	-9.0012	3.2806
3f	-5.8308	-9.1160	3.2852
3g	-5.7962	-9.3231	3.5269
3h	-5.7775	-9.1544	3.3769
5a	-5.1511	-8.5408	3.3897
5b	-5.1040	-8.4167	3.3127
5c	-5.0251	-8.1794	3.1543
5d	-5.3217	-8.6695	3.3478
5e	-5.3013	-8.6377	3.3364
5f	-5.0958	-8.4758	3.38
5g	-5.0039	-8.3479	3.344
5h	-5.0814	-8.1149	3.0335
5i	-4.605	-7.466	2.86
5j	-5.31873	-8.6741	3.3553
5k	-5.0436	-8.3190	3.2754
5k'	-5.12689	-8.48288	3.3559
5l	-5.2531	-8.5745	3.3214
5l'	-5.2466	-8.5773	3.3307




Figure S99: HOMO-LUMO of the compound **3a**




Figure S100: HOMO-LUMO of the compound **3b**




Figure S101: HOMO-LUMO of the compound 3c




Figure S102: HOMO-LUMO of the compound 3d




Figure S103: HOMO-LUMO of the compound 3e




Figure S104: HOMO-LUMO of the compound 3f




Figure S105: HOMO-LUMO of the compound **3g**




Figure S106: HOMO-LUMO of the compound **3h**




Figure S107: HOMO-LUMO of the compound 5a




Figure S108: HOMO-LUMO of the compound 5b




Figure S109: HOMO-LUMO of the compound 5c




Figure S110: HOMO-LUMO of the compound 5d




Figure S111: HOMO-LUMO of the compound 5e




Figure S112: HOMO-LUMO of the compound 5f




Figure S113: HOMO-LUMO of the compound 5g




Figure S114: HOMO-LUMO of the compound 5h




Figure S115: HOMO-LUMO of the compound 5i




Figure S116: HOMO-LUMO of the compound 5j




Figure S117: HOMO-LUMO of the compound 5k




Figure S118: HOMO-LUMO of the compound 5l

6. Reference

1. Gaussian 16, Revision **C.01**, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, **2016**.